Dear colleagues, 

my name is Fotini Stasini and I am a nephrologist from Greece. 

21 days after the second dose of the COVID vaccine, I developed a rash. 

The biopsy showed vasculitis and spongiotic dermatitis.

I send you photos and tests of mine.

If you have reports of patients receiving a second dose or booster after cutaneous reactions, I would like your advice if I could receive the third dose.

Pfizer does not have any recommendations regarding the management of spongiotic dermatitis in patients receiving Comirnaty (also referred to as BNT162b2).

Pfizer suggests that clinical judgement based on the medical history and the clinical status of a specific patient should dictate the appropriate actions to be taken.

Sincerely,

Fotini Stasini MD PhD

• Paciente masculino de 19 años con antecedentes de alergia a polvo, ácaros y colorante. Reacción alérgica post vacuna 10 minutos después.

Deseo saber con qué frecuencia se presentan estos síntomas al momento de la segunda dosis.

Las lesiones desaparecieron con una dosis de loratadina pero reaparecieron.

Patient 58 years old.  She has a history of autoinuclear theriiditis, atrial fibrillation in a state of compensation. On August 11, she received a Modern vaccine.  After this, the throat swelled, heart palpitations began, runny nose, annual pain.  PCR on covid did not.  The second vaccination is scheduled for October 9th.  I came to the appointment with pllnrgicheskoy dermatitis and asked what to do, what would the second vaccination to transfer the legse.  In the analysis of blood, the basovil is increased.  increased TSH, and the s-protein is 9286 at a rate of up to 50 .. What to recommend: 1. Transfer the second dose to a later period 2. Refuse the second dose 3. Prescribe medication support 4. Fifth version: I will be grateful and not any hint

WEDNESDAY, July 12, 2023 (HealthDay News) -- The prevalence of atopic diseases, including atopic dermatitis, is increased in sexually diverse people, including those who identify as lesbian, gay, or bisexual, according to a research letter published online July 12 in JAMA Dermatology.

Katelyn J. Rypka, from the University of Minnesota Medical School in Minneapolis, and colleagues calculated crude and multivariable-adjusted odd ratios for prevalence of atopic dermatitis, asthma, and allergic rhinitis comparing heterosexual and sexually diverse individuals. Data were included for 27,012 respondents to the 2021 National Health Interview Survey, of whom 25,701 were heterosexual and 1,311 were sexually diverse.

The researchers found that sexually diverse individuals were more likely to report atopic dermatitis (11.1 versus 7.2 percent), asthma (12.0 versus 7.8 percent), and allergic rhinitis (33.7 versus 25.6 percent) compared with heterosexual individuals (adjusted odds ratios, 1.49, 1.39, and 1.30, respectively). In sex-stratified analyses, results were similar.

"This study found higher rates of atopic disease among sexually diverse individuals," the authors write. "Further research is needed to identify factors contributing to these differences, including environmental, socioeconomic, and sociocultural factors and minority stress."

Abstract/Full Text (subscription or payment may be required)

Copyright © 2020 HealthDay. All rights reserved.

WEDNESDAY, June 28, 2023 (HealthDay News) -- Crisaborole is effective as a long-term maintenance therapy for pediatric and adult patients with mild-to-moderate atopic dermatitis (AD), according to a study published online May 15 in the American Journal of Clinical Dermatology.

Lawrence F. Eichenfield, M.D., from the University of California San Diego and Rady Children's Hospital-San Diego, and colleagues examined long-term efficacy and safety of crisaborole once daily (QD) versus vehicle QD as maintenance therapy for patients (aged ≥3 months) with mild-to-moderate AD. Eligible patients received crisaborole twice daily during an open-label run-in period of up to eight weeks and were then randomly assigned to receive crisaborole or vehicle QD (135 patients in each group).

The researchers found that patients who received crisaborole versus vehicle had longer median time of flare-free maintenance (111 versus 30 days). For patients who received crisaborole versus vehicle, the mean number of flare-free days was higher (234.0 versus 199.4 days). In addition, patients receiving crisaborole had a lower mean number of flares (0.95 versus 1.36). No clear trend was observed between the groups in maintenance of pruritus response. Crisaborole was well tolerated, with no new safety findings for use as maintenance treatment.

"Crisaborole QD is effective as a long-term maintenance therapy, demonstrating a significant reduction in the incidence of AD-related flares compared to vehicle in pediatric (aged ≥3 months) and adult patients with mild-to-moderate AD," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including Pfizer, which manufactures crisaborole and funded the study.

Abstract/Full Text

Copyright © 2020 HealthDay. All rights reserved.

CD8+ T Cells Trigger Auricular Dermatitis and Blepharitis in Mice after Zika Virus Infection in the Absence of CD4+… https://t.co/AMGtjKZWLKJune 08,2023